These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

266 related items for PubMed ID: 23484796

  • 21. Bleeding in Patients of African Ancestry Using Dabigatran: A Potential Effect of Creatine Kinase.
    Horjus DL, van Montfrans GA, Brewster LM.
    JAMA Intern Med; 2015 Jul; 175(7):1243. PubMed ID: 26146917
    [No Abstract] [Full Text] [Related]

  • 22. One-Year Risk of Bleeding With Dabigatran in Patients With Atrial Fibrillation: Placing Real-World Results Into Perspective.
    Miyares MA.
    JAMA Intern Med; 2015 Jul; 175(7):1242-3. PubMed ID: 26146916
    [No Abstract] [Full Text] [Related]

  • 23. A Methodological Appraisal of Recent Real-World Data Publications on Dabigatran.
    Zint K, Kreuzer J.
    JAMA Intern Med; 2015 Jul; 175(7):1244. PubMed ID: 26146919
    [No Abstract] [Full Text] [Related]

  • 24. Bleeding events among new starters and switchers to dabigatran compared with warfarin in atrial fibrillation.
    Larsen TB, Gorst-Rasmussen A, Rasmussen LH, Skjøth F, Rosenzweig M, Lip GY.
    Am J Med; 2014 Jul; 127(7):650-656.e5. PubMed ID: 24530792
    [Abstract] [Full Text] [Related]

  • 25. Concerns over data in key dabigatran trial.
    Cohen D.
    BMJ; 2014 Jul 23; 349():g4747. PubMed ID: 25055831
    [No Abstract] [Full Text] [Related]

  • 26. Intensity and quality of warfarin anticoagulation in Chinese patients: setting the record straight.
    Eikelboom JW, Hart RG.
    Stroke; 2015 Jan 23; 46(1):5-6. PubMed ID: 25406147
    [No Abstract] [Full Text] [Related]

  • 27. [New oral anticoagulants and digestive hemorrhages].
    Diallo I, Mallaret C, Jourdan S, Brardjanian S, Guisset M, Coton T.
    Presse Med; 2014 Jan 23; 43(1):85-7. PubMed ID: 23706679
    [No Abstract] [Full Text] [Related]

  • 28. Intracranial hemorrhage during dabigatran treatment.
    Komori M, Yasaka M, Kokuba K, Matsuoka H, Fujimoto S, Yoshida M, Kameda K, Shono T, Nagata S, Ago T, Kitazono T, Okada Y.
    Circ J; 2014 Jan 23; 78(6):1335-41. PubMed ID: 24662438
    [Abstract] [Full Text] [Related]

  • 29. Risk of major bleeding and the standard doses of dabigatran.
    Antoniazzi S, Berdaï D, Conti V, Clementi E, Salvo F.
    Eur J Intern Med; 2014 Jul 23; 25(6):e73-5. PubMed ID: 24629895
    [No Abstract] [Full Text] [Related]

  • 30. Risks for stroke, bleeding, and death in patients with atrial fibrillation receiving dabigatran or warfarin in relation to the CHADS2 score: a subgroup analysis of the RE-LY trial.
    Oldgren J, Alings M, Darius H, Diener HC, Eikelboom J, Ezekowitz MD, Kamensky G, Reilly PA, Yang S, Yusuf S, Wallentin L, Connolly SJ, RE-LY Investigators.
    Ann Intern Med; 2011 Nov 15; 155(10):660-7, W204. PubMed ID: 22084332
    [Abstract] [Full Text] [Related]

  • 31. Effects of recombinant factor VIIa on thrombin generation and thromboelastography in a patient with dabigatran-associated intracranial hemorrhage.
    Aron JL, Gosselin R, Moll S, Arkin CF, Mantha S.
    J Thromb Thrombolysis; 2014 Nov 15; 37(2):76-9. PubMed ID: 23519385
    [No Abstract] [Full Text] [Related]

  • 32. Application of the RELY study to lifetime risks of atrial fibrillation: implications for spontaneous intracranial hemorrhage.
    Parry PV, Engh JA.
    Neurosurgery; 2012 Feb 15; 70(2):N10-1. PubMed ID: 22251978
    [No Abstract] [Full Text] [Related]

  • 33. Hemorrhagic complications in emergency department patients who are receiving dabigatran compared with warfarin.
    Berger R, Salhanick SD, Chase M, Ganetsky M.
    Ann Emerg Med; 2013 Apr 15; 61(4):475-9. PubMed ID: 23522810
    [Abstract] [Full Text] [Related]

  • 34. Risk of gastrointestinal bleeding associated with oral anticoagulants: population based retrospective cohort study.
    Chang HY, Zhou M, Tang W, Alexander GC, Singh S.
    BMJ; 2015 Apr 24; 350():h1585. PubMed ID: 25911526
    [Abstract] [Full Text] [Related]

  • 35. Evaluation of Dabigatran- and Warfarin-Associated Hemorrhagic Events Using the FDA-Adverse Event Reporting System Database Stratified by Age.
    Abe J, Umetsu R, Kato Y, Ueda N, Nakayama Y, Suzuki Y, Suzuki T, Nagasawa H, Kinosada Y, Nakamura M.
    Int J Med Sci; 2015 Apr 24; 12(4):312-21. PubMed ID: 25897292
    [Abstract] [Full Text] [Related]

  • 36. Dabigatran: how the drug company withheld important analyses.
    Cohen D.
    BMJ; 2014 Jul 23; 349():g4670. PubMed ID: 25055829
    [No Abstract] [Full Text] [Related]

  • 37. Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
    Majeed A, Hwang HG, Connolly SJ, Eikelboom JW, Ezekowitz MD, Wallentin L, Brueckmann M, Fraessdorf M, Yusuf S, Schulman S.
    Circulation; 2013 Nov 19; 128(21):2325-32. PubMed ID: 24081972
    [Abstract] [Full Text] [Related]

  • 38. Anticoagulant options--why the FDA approved a higher but not a lower dose of dabigatran.
    Beasley BN, Unger EF, Temple R.
    N Engl J Med; 2011 May 12; 364(19):1788-90. PubMed ID: 21488759
    [No Abstract] [Full Text] [Related]

  • 39. New era of oral anticoagulation for Japanese non-valvular atrial fibrillation patients.
    Hirano T.
    Circ J; 2014 May 12; 78(6):1317-9. PubMed ID: 24805358
    [No Abstract] [Full Text] [Related]

  • 40. Dabigatran "non-inferior" to warfarin, but only just.
    BMJ; 2013 Feb 27; 346():f1219. PubMed ID: 23447339
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.